KLK3 and prostate carcinoma: Some reports have identified SII as a significant diagnostic marker for patients with PSA levels below 10 ng/ml in prostate fusion biopsy (26), with the combined diagnostic efficiency of SII and PSA for prostate cancer surpassing that of PSA alone (27).